Astrazeneca Stock – Australia has its second likely AstraZeneca vaccine blood-clot case
CANBERRA, Australia — Australian authorities have identified a second case of a rare blot clot likely linked to the AstraZeneca coronavirus vaccine.
Australia has administered 700,000 doses of the AstraZeneca vaccine since early March. That equates to a clotting frequency of 1-in-350,000 cases. British authorities say the risk of such blood clots has been 1-in-250,000 in that country.
Australia had planned to rely on Australian-manufactured AstraZeneca for delivering at least one dose of a vaccine to all eligible adults among its population of 26 million by October. But it said last week the Pfizer
vaccine is now the preferred option for people under 50 because of the potential risk from AstraZeneca.